dtil-10q_20210930.htm
false Q3 2021 PRECISION BIOSCIENCES INC 0001357874 --12-31 P1Y P6Y1M28D P6Y4M9D 0001357874 2021-01-01 2021-09-30 xbrli:shares 0001357874 2021-11-03 iso4217:USD 0001357874 2021-09-30 0001357874 2020-12-31 iso4217:USD xbrli:shares 0001357874 2021-07-01 2021-09-30 0001357874 2020-07-01 2020-09-30 0001357874 2020-01-01 2020-09-30 0001357874 us-gaap:CommonStockMember 2019-12-31 0001357874 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001357874 us-gaap:RetainedEarningsMember 2019-12-31 0001357874 us-gaap:TreasuryStockMember 2019-12-31 0001357874 2019-12-31 0001357874 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001357874 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001357874 2020-01-01 2020-03-31 0001357874 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001357874 us-gaap:CommonStockMember 2020-03-31 0001357874 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001357874 us-gaap:RetainedEarningsMember 2020-03-31 0001357874 us-gaap:TreasuryStockMember 2020-03-31 0001357874 2020-03-31 0001357874 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001357874 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001357874 2020-04-01 2020-06-30 0001357874 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001357874 us-gaap:CommonStockMember 2020-06-30 0001357874 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001357874 us-gaap:RetainedEarningsMember 2020-06-30 0001357874 us-gaap:TreasuryStockMember 2020-06-30 0001357874 2020-06-30 0001357874 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001357874 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001357874 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001357874 us-gaap:CommonStockMember 2020-09-30 0001357874 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001357874 us-gaap:RetainedEarningsMember 2020-09-30 0001357874 us-gaap:TreasuryStockMember 2020-09-30 0001357874 2020-09-30 0001357874 us-gaap:CommonStockMember 2020-12-31 0001357874 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001357874 us-gaap:RetainedEarningsMember 2020-12-31 0001357874 us-gaap:TreasuryStockMember 2020-12-31 0001357874 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001357874 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001357874 2021-01-01 2021-03-31 0001357874 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001357874 us-gaap:CommonStockMember 2021-03-31 0001357874 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001357874 us-gaap:RetainedEarningsMember 2021-03-31 0001357874 us-gaap:TreasuryStockMember 2021-03-31 0001357874 2021-03-31 0001357874 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001357874 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001357874 2021-04-01 2021-06-30 0001357874 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001357874 us-gaap:CommonStockMember 2021-06-30 0001357874 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001357874 us-gaap:RetainedEarningsMember 2021-06-30 0001357874 us-gaap:TreasuryStockMember 2021-06-30 0001357874 2021-06-30 0001357874 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001357874 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001357874 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001357874 us-gaap:CommonStockMember 2021-09-30 0001357874 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001357874 us-gaap:RetainedEarningsMember 2021-09-30 0001357874 us-gaap:TreasuryStockMember 2021-09-30 0001357874 dtil:PrecisionPlantSciencesIncMember 2021-01-01 2021-09-30 xbrli:pure 0001357874 dtil:PrecisionPlantSciencesIncMember 2021-09-30 0001357874 dtil:EloLifeSystemsAustraliaPtyLtdMember srt:SubsidiaryIssuerMember 2021-09-30 0001357874 dtil:EloLifeSystemsAustraliaPtyLtdMember srt:SubsidiaryIssuerMember 2021-01-01 2021-09-30 0001357874 dtil:PrecisionBioSciencesUKLimitedMember 2021-09-30 0001357874 dtil:PrecisionBioSciencesUKLimitedMember 2021-01-01 2021-09-30 0001357874 srt:MaximumMember 2021-01-01 2021-09-30 0001357874 2019-04-01 0001357874 dtil:TwoThousandSixAndTwoThousandFifteenStockIncentivePlanMember 2021-09-30 0001357874 dtil:TwoThousandNineteenIncentiveAwardPlanMember 2019-03-12 0001357874 dtil:TwoThousandNineteenIncentiveAwardPlanMember 2021-09-30 0001357874 dtil:TwoThousandNineteenIncentiveAwardPlanMember 2019-03-11 2019-03-12 0001357874 dtil:TwoThousandNineteenIncentiveAwardPlanMember us-gaap:RestrictedStockUnitsRSUMember 2021-09-30 0001357874 dtil:TwoThousandNineteenEmployeeStockPurchasePlanMember 2019-03-12 0001357874 dtil:TwoThousandNineteenEmployeeStockPurchasePlanMember 2021-09-30 0001357874 dtil:TwoThousandNineteenEmployeeStockPurchasePlanMember 2019-03-11 2019-03-12 0001357874 dtil:TwoThousandNineteenEmployeeStockPurchasePlanMember dtil:EmployeeStockPurchasePlanMember 2019-03-12 0001357874 dtil:EmployeeStockPurchasePlanMember 2021-01-01 2021-09-30 0001357874 dtil:EmployeeStockPurchasePlanMember 2020-01-01 2020-09-30 0001357874 dtil:InducementAwardPlanMember 2021-08-09 0001357874 us-gaap:ShareBasedPaymentArrangementEmployeeMember 2021-07-01 2021-09-30 0001357874 us-gaap:ShareBasedPaymentArrangementEmployeeMember 2020-07-01 2020-09-30 0001357874 us-gaap:ShareBasedPaymentArrangementEmployeeMember 2021-01-01 2021-09-30 0001357874 us-gaap:ShareBasedPaymentArrangementEmployeeMember 2020-01-01 2020-09-30 0001357874 us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2021-07-01 2021-09-30 0001357874 us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2020-07-01 2020-09-30 0001357874 us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2021-01-01 2021-09-30 0001357874 us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2020-01-01 2020-09-30 0001357874 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:EmployeeStockOptionMember 2021-07-01 2021-09-30 0001357874 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:EmployeeStockOptionMember 2020-07-01 2020-09-30 0001357874 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:EmployeeStockOptionMember 2021-01-01 2021-09-30 0001357874 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0001357874 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:EmployeeStockOptionMember 2021-07-01 2021-09-30 0001357874 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:EmployeeStockOptionMember 2020-07-01 2020-09-30 0001357874 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:EmployeeStockOptionMember 2021-01-01 2021-09-30 0001357874 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0001357874 us-gaap:EmployeeStockOptionMember 2021-07-01 2021-09-30 0001357874 us-gaap:EmployeeStockOptionMember 2020-07-01 2020-09-30 0001357874 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-09-30 0001357874 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0001357874 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-09-30 0001357874 us-gaap:RestrictedStockUnitsRSUMember 2021-09-30 0001357874 us-gaap:ResearchAndDevelopmentExpenseMember 2021-09-30 0001357874 srt:MaximumMember 2021-04-09 2021-04-09 0001357874 us-gaap:RevolvingCreditFacilityMember dtil:PacificWesternLoanAgreementMember 2019-05-31 0001357874 dtil:PacificWesternLoanAgreementMember srt:MinimumMember us-gaap:RevolvingCreditFacilityMember 2021-09-30 0001357874 dtil:PacificWesternLoanAgreementMember us-gaap:RevolvingCreditFacilityMember 2021-01-01 2021-09-30 0001357874 dtil:PacificWesternLoanAgreementMember us-gaap:RevolvingCreditFacilityMember 2021-09-30 0001357874 dtil:EloLoanMember 2021-05-19 0001357874 dtil:EloLoanMember 2021-05-19 2021-05-19 0001357874 dtil:EloLoanMember srt:MaximumMember 2021-05-19 0001357874 2021-01-01 2021-12-31 0001357874 dtil:PacificWesternBankMember 2021-05-19 2021-05-19 0001357874 srt:ScenarioForecastMember 2022-03-31 2022-03-31 0001357874 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001357874 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2021-09-30 0001357874 us-gaap:RepurchaseAgreementsMember us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001357874 us-gaap:RepurchaseAgreementsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2021-09-30 0001357874 dtil:InvestmentInIECUREMember us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001357874 dtil:InvestmentInIECUREMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2021-09-30 0001357874 us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001357874 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2021-09-30 0001357874 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2021-09-30 0001357874 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2021-09-30 0001357874 us-gaap:FairValueMeasurementsRecurringMember dtil:WarrantLiabilityMember 2021-09-30 0001357874 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member dtil:WarrantLiabilityMember 2021-09-30 0001357874 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001357874 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0001357874 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001357874 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0001357874 us-gaap:ResearchAndDevelopmentArrangementMember dtil:EliLillyAndCompanyMember 2021-01-05 2021-01-06 0001357874 us-gaap:ResearchAndDevelopmentArrangementMember dtil:EliLillyAndCompanyMember dtil:StockPurchaseAgreementMember 2021-01-06 0001357874 us-gaap:ResearchAndDevelopmentArrangementMember dtil:EliLillyAndCompanyMember dtil:StockPurchaseAgreementMember 2021-01-05 2021-01-06 0001357874 dtil:EliLillyAndCompanyMember us-gaap:ResearchAndDevelopmentArrangementMember 2021-01-01 2021-09-30 0001357874 dtil:EliLillyAndCompanyMember us-gaap:ResearchAndDevelopmentArrangementMember 2020-01-01 2020-12-31 0001357874 dtil:EliLillyAndCompanyMember us-gaap:ResearchAndDevelopmentArrangementMember 2021-09-30 0001357874 dtil:EliLillyAndCompanyMember us-gaap:ResearchAndDevelopmentArrangementMember 2020-12-31 0001357874 dtil:EliLillyAndCompanyMember us-gaap:ResearchAndDevelopmentArrangementMember dtil:CurrentLiabilitiesMember 2021-09-30 0001357874 dtil:IECUREMember us-gaap:ResearchAndDevelopmentArrangementMember 2021-08-09 0001357874 dtil:IECUREMember us-gaap:ResearchAndDevelopmentArrangementMember 2021-09-30 0001357874 us-gaap:ResearchAndDevelopmentArrangementMember dtil:IECUREMember 2021-01-01 2021-09-30 0001357874 us-gaap:ResearchAndDevelopmentArrangementMember dtil:IECUREMember 2020-01-01 2020-12-31 0001357874 dtil:ProgramPurchaseAgreementMember dtil:ServierMember 2021-04-09 2021-04-09 0001357874 dtil:DevelopmentAndCommercialLicenseAgreementMember dtil:ServierMember 2021-01-01 2021-09-30 0001357874 dtil:DevelopmentAndCommercialLicenseAgreementMember dtil:ServierMember 2020-01-01 2020-09-30 0001357874 dtil:DevelopmentAndCommercialLicenseAgreementMember dtil:ServierMember 2021-09-30 0001357874 dtil:DevelopmentAndCommercialLicenseAgreementMember dtil:ServierMember 2020-12-31 0001357874 dtil:DevelopmentAndCommercialLicenseAgreementMember dtil:ServierMember dtil:CurrentLiabilitiesMember 2020-12-31 0001357874 dtil:CollaborationAndLicenseAgreementMember dtil:GileadSciencesIncMember 2021-01-01 2021-09-30 0001357874 dtil:CollaborationAndLicenseAgreementMember dtil:GileadSciencesIncMember 2020-01-01 2020-09-30 0001357874 dtil:CollaborationAndLicenseAgreementMember dtil:GileadSciencesIncMember 2021-09-30 0001357874 dtil:CollaborationAndLicenseAgreementMember dtil:GileadSciencesIncMember 2020-12-31 0001357874 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-09-30 0001357874 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-09-30 0001357874 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 dtil:Segment 0001357874 dtil:TherapeuticsSegmentMember us-gaap:OperatingSegmentsMember 2021-07-01 2021-09-30 0001357874 dtil:TherapeuticsSegmentMember us-gaap:OperatingSegmentsMember 2020-07-01 2020-09-30 0001357874 dtil:FoodSegmentMember us-gaap:OperatingSegmentsMember 2021-07-01 2021-09-30 0001357874 dtil:FoodSegmentMember us-gaap:OperatingSegmentsMember 2020-07-01 2020-09-30 0001357874 us-gaap:OperatingSegmentsMember 2021-07-01 2021-09-30 0001357874 us-gaap:OperatingSegmentsMember 2020-07-01 2020-09-30 0001357874 us-gaap:MaterialReconcilingItemsMember 2021-07-01 2021-09-30 0001357874 us-gaap:MaterialReconcilingItemsMember 2020-07-01 2020-09-30 0001357874 dtil:TherapeuticsSegmentMember us-gaap:OperatingSegmentsMember 2021-01-01 2021-09-30 0001357874 dtil:TherapeuticsSegmentMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-09-30 0001357874 dtil:FoodSegmentMember us-gaap:OperatingSegmentsMember 2021-01-01 2021-09-30 0001357874 dtil:FoodSegmentMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-09-30 0001357874 us-gaap:OperatingSegmentsMember 2021-01-01 2021-09-30 0001357874 us-gaap:OperatingSegmentsMember 2020-01-01 2020-09-30 0001357874 us-gaap:MaterialReconcilingItemsMember 2021-01-01 2021-09-30 0001357874 us-gaap:MaterialReconcilingItemsMember 2020-01-01 2020-09-30 0001357874 dtil:InducementAwardPlanMember srt:ChiefExecutiveOfficerMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2021-10-15 2021-10-15 0001357874 dtil:InducementAwardPlanMember srt:ChiefExecutiveOfficerMember us-gaap:SubsequentEventMember us-gaap:RestrictedStockMember 2021-10-15 2021-10-15 0001357874 dtil:InducementAwardPlanMember srt:ChiefExecutiveOfficerMember us-gaap:SubsequentEventMember 2021-10-15

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 10-Q

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2021

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-38841

 

Precision BioSciences, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

 

Delaware

20-4206017

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

302 East Pettigrew St., Suite A-100

Durham, North Carolina

27701

(Address of principal executive offices)

(Zip Code)

 

(919) 314-5512

(Registrant’s telephone number, including area code)

 

N/A

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

 

 

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.000005 per share

DTIL

The Nasdaq Global Select Market

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     Yes      No  

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes      No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

Accelerated filer

Non-accelerated filer

 

Smaller reporting company

 

 

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No 

As November 3, 2021, the registrant had 60,767,307 shares of common stock, $0.000005 par value per share, outstanding.

 

 

 


 

Table of Contents

 

 

 

Page

 

Forward-Looking Statements

3

 

Risk Factor Summary

6

PART I.

FINANCIAL INFORMATION

7

Item 1.

Financial Statements

7

 

Condensed Consolidated Balance Sheets

7

 

Condensed Consolidated Statements of Operations

8

 

Condensed Consolidated Statements of Changes in Stockholders’ Equity

9

 

Condensed Consolidated Statements of Cash Flows

10

 

Notes to Unaudited Condensed Consolidated Financial Statements

11

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

25

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

41

Item 4.

Controls and Procedures

41

PART II.

OTHER INFORMATION

42

Item 1.

Legal Proceedings

42

Item 1A.

Risk Factors

42

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

93

Item 3.

Defaults Upon Senior Securities

93

Item 4.

Mine Safety Disclosures

93

Item 5.

Other Information

93

Item 6.

Exhibits

94

 

Signatures

96

 

 

 

 

2


 

FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements other than statements of present and historical facts contained in this Quarterly Report on Form 10-Q, including without limitation, statements regarding our future results of operations and financial position, business strategy and approach, including related results, prospective products, planned preclinical or greenhouse studies and clinical or field trials, the status and results of our preclinical and clinical studies, expected release of interim data, expectations regarding our allogeneic chimeric antigen receptor T cell immunotherapy product candidates, expectations regarding the use and effects of ARCUS, including in connection with in vivo genome editing, potential new partnerships or alternative opportunities for our product candidates, capabilities of our manufacturing facility, regulatory approvals, research and development costs, timing, expected results and likelihood of success, plans and objectives of management for future operations, as well as the impact of COVID-19 and variants thereof may be forward-looking statements. Without limiting the foregoing, in some cases, you can identify forward-looking statements by terms such as “aim,” “may,” “will,” “should,” “expect,” “exploring,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential,” “seeks,” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. No forward-looking statement is a guarantee of future results, performance, or achievements, and one should avoid placing undue reliance on such statements.

Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to us. Such beliefs and assumptions may or may not prove to be correct. Additionally, such forward-looking statements are subject to a number of known and unknown risks, uncertainties and assumptions, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including, but not limited to, those identified in Part I. Item 2. “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and Part II. Item 1A. “Risk Factors.” These risks and uncertainties include, but are not limited to:

 

our ability to become profitable;

 

our ability to procure sufficient funding and requirements under our current debt instruments and effects of restrictions thereunder;

 

risks associated with raising additional capital;

 

our operating expenses and our ability to predict what those expenses will be;

 

our limited operating history;

 

the success of our programs and product candidates in which we expend our resources;

 

our dependence on our ARCUS technology;

 

the risk that other genome-editing technologies may provide significant advantages over our ARCUS technology;

 

the initiation, cost, timing, progress, achievement of milestones and results of research and development activities, preclinical or greenhouse studies and clinical or field trials;

 

public perception about genome editing technology and its applications;

 

competition in the genome editing, biopharmaceutical, biotechnology and agricultural biotechnology fields;

 

our or our collaborators’ ability to identify, develop and commercialize product candidates;

3


 

 

pending and potential liability lawsuits and penalties against us or our collaborators related to our technology and our product candidates;

 

the U.S. and foreign regulatory landscape applicable to our and our collaborators’ development of product candidates;

 

our or our collaborators’ ability to obtain and maintain regulatory approval of our product candidates, and any related restrictions, limitations and/or warnings in the label of an approved product candidate;

 

our or our collaborators’ ability to advance product candidates into, and successfully design, implement and complete, clinical or field trials;

 

potential manufacturing problems associated with the development or commercialization of any of our product candidates;

 

our ability to obtain an adequate supply of T cells from qualified donors;

 

our ability to achieve our anticipated operating efficiencies at our manufacturing facility;

 

delays or difficulties in our and our collaborators’ ability to enroll patients;

 

changes in interim “top-line” data that we announce or publish;

 

if our product candidates do not work as intended or cause undesirable side effects;

 

risks associated with applicable healthcare, data privacy and security regulations and our compliance therewith;

 

the rate and degree of market acceptance of any of our product candidates;

 

the success of our existing collaboration agreements, and our ability to enter into new collaboration arrangements;

 

our current and future relationships with third parties including suppliers and manufacturers;

 

our ability to obtain and maintain intellectual property protection for our technology and any of our product candidates;

 

potential litigation relating to infringement or misappropriation of intellectual property rights;

 

our ability to effectively manage the growth of our operations;

 

our ability to attract, retain, and motivate key scientific and management personnel;

 

market and economic conditions;

 

effects of system failures and security breaches;

 

effects of natural and manmade disasters, public health emergencies and other natural catastrophic events;

 

effects of COVID-19 and variants thereof, or any pandemic, epidemic, or outbreak of an infectious disease;

 

insurance expenses and exposure to uninsured liabilities;

 

effects of tax rules; and

 

risks related to ownership of our common stock, including fluctuations in our stock price.

4


 

 

Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties.

You should read this Quarterly Report on Form 10-Q and the documents that we reference herein completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. All forward-looking statements contained herein speak only as of the date of this Quarterly Report on Form 10-Q. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

As used in this Quarterly Report on Form 10-Q, unless otherwise stated or the context requires otherwise, references to “Precision,” the “Company,” “we,” “us,” and “our,” refer to Precision BioSciences, Inc. and its subsidiaries on a consolidated basis.

 


5


 

RISK FACTOR SUMMARY

Our business is subject to numerous risks and uncertainties, including those described in Part II. Item 1A. “Risk Factors” in this Quarterly Report on Form 10-Q. You should carefully consider these risks and uncertainties when investing in our common stock. Some of the principal risks and uncertainties include the following.

 

We have incurred significant operating losses since our inception and expect to continue to incur losses for the foreseeable future. We have never been profitable and may never achieve or maintain profitability.

 

We will need substantial additional funding, and if we are unable to raise a sufficient amount of capital when needed on acceptable terms, or at all, we may be forced to delay, reduce or eliminate some or all of our research programs, product development activities and commercialization efforts.

 

We have a limited operating history, which makes it difficult to evaluate our current business and future prospects and may increase the risk of your investment.

 

ARCUS is a novel technology, making it difficult to predict the time, cost and potential success of product candidate development. We have not yet been able to assess the safety and efficacy of most of our product candidates in humans and have only limited safety and efficacy information in humans to date regarding three of our product candidates.

 

We are heavily dependent on the successful development and translation of ARCUS, and due to the early stages of our product development operations, we cannot give any assurance that any product candidates will be successfully developed and commercialized.

 

Adverse public perception of genome editing may negatively impact the developmental progress or commercial success of products that we develop alone or with collaborators.

 

We face significant competition in industries experiencing rapid technological change, and there is a possibility that our competitors may achieve regulatory approval before us or develop product candidates or treatments that are safer or more effective than ours, which may harm our financial condition and our ability to successfully market or commercialize any of our product candidates.

 

Our future profitability, if any, depends in part on our and our collaborators’ ability to penetrate global markets, where we would be subject to additional regulatory burdens and other risks and uncertainties associated with international operations that could materially adversely affect our business.

 

Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any products that we develop alone or with collaborators.

 

The regulatory landscape that will apply to development of therapeutic product candidates by us or our collaborators is rigorous, complex, uncertain and subject to change, which could result in delays or termination of development of such product candidates or unexpected costs in obtaining regulatory approvals.

 

Clinical trials are difficult to design and implement, expensive, time-consuming and involve an uncertain outcome, and the inability to successfully and timely conduct clinical trials and obtain regulatory approval for our product candidates would substantially harm our business.

 

Even if we obtain regulatory approval for any products that we develop alone or with collaborators, such products will remain subject to ongoing regulatory requirements, which may result in significant additional expense.

 

Even if any product we develop alone or with collaborators receives marketing approval, such product may fail to achieve the degree of market acceptance by physicians, patients, healthcare payors and others in the medical community necessary for commercial success.

 

The ongoing novel coronavirus disease, COVID-19, has impacted our business and any other pandemic, epidemic or outbreak of an infectious disease may materially and adversely impact our business, including our preclinical studies and clinical trials.

6


Part I. Financial information

 

Item 1.  Financial Statements.

Precision Biosciences, Inc.

Condensed Consolidated Balance Sheets

(In thousands, except share and per share amounts)

(Unaudited)

 

 

 

September 30, 2021

 

 

December 31, 2020

 

Assets

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

160,471

 

 

$

89,798

 

Accounts receivable

 

 

488

 

 

 

10,000

 

Prepaid expenses

 

 

21,191

 

 

 

5,762

 

Other current assets

 

 

898

 

 

 

4

 

Total current assets

 

 

183,048

 

 

 

105,564

 

Property, equipment, and software—net

 

 

31,536

 

 

 

35,090

 

Intangible assets—net

 

 

2,074

 

 

 

1,373

 

Right-of-use assets—net

 

 

5,513

 

 

 

6,410

 

Investment in equity securities

 

 

812

 

 

 

 

Other assets

 

 

4,216

 

 

 

1,721

 

Total assets

 

$

227,199

 

 

$

150,158

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

486

 

 

$

792

 

Accrued compensation

 

 

4,548

 

 

 

5,745

 

Accrued clinical and research and development expenses

 

 

3,008

 

 

 

3,269

 

Deferred revenue

 

 

21,976

 

 

 

30,236

 

Lease liabilities

 

 

2,123

 

 

 

1,933

 

Loan payable—net

 

 

2,454

 

 

 

 

Other current liabilities

 

 

1,880

 

 

 

854

 

Total current liabilities

 

 

36,475

 

 

 

42,829

 

Deferred revenue

 

 

71,838

 

 

 

53,926

 

Lease liabilities

 

 

6,966

 

 

 

8,586

 

Contract liabilities

 

 

10,000

 

 

 

 

Other liabilities

 

 

477

 

 

 

392

 

Total liabilities

 

 

125,756

 

 

 

105,733

 

Commitments and contingencies (Note 4)

 

 

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

 

 

Preferred stock, $0.0001 par value— 10,000,000 shares authorized as of September 30, 2021 and December 31, 2020; no shares issued and outstanding as of September 30, 2021 and December 31, 2020

 

 

 

 

 

 

Common stock; $0.000005 par value— 200,000,000 shares authorized as of September 30, 2021 and December 31, 2020; 60,892,018 shares issued and 60,081,546 shares outstanding as of September 30, 2021; 53,503,124 shares issued and 52,692,652 shares outstanding as of December 31, 2020

 

 

 

 

 

 

Additional paid-in capital

 

 

396,780

 

 

 

331,450

 

Accumulated deficit

 

 

(294,385

)

 

 

(286,073

)

Treasury stock

 

 

(952

)

 

 

(952

)

Total stockholders’ equity

 

 

101,443

 

 

 

44,425

 

Total liabilities and stockholders’ equity

 

$

227,199

 

 

$

150,158

 

 

See notes to condensed consolidated financial statements

7


Precision Biosciences, Inc.

Condensed Consolidated Statements of Operations

(In thousands, except share and per share amounts)

(Unaudited)

 

 

 

For the Three Months Ended September 30,

 

 

For the Nine Months Ended September 30,

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

Revenue

 

$

24,036

 

 

$

7,363

 

 

$

109,190

 

 

$

15,439

 

Operating expenses

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

25,940

 

 

 

24,873

 

 

 

88,768

 

 

 

74,935

 

General and administrative

 

 

9,638

 

 

 

8,534

 

 

 

29,074

 

 

 

26,852

 

Total operating expenses

 

 

35,578

 

 

 

33,407

 

 

 

117,842

 

 

 

101,787

 

Operating loss

 

 

(11,542

)

 

 

(26,044

)

 

 

(8,652

)

 

 

(86,348

)

Other income (expense):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Change in fair value of equity investment

 

 

274

 

 

 

 

 

 

274

 

 

 

 

Interest expense

 

 

(55

)

 

 

 

 

 

(79

)

 

 

 

Interest income

 

 

44

 

 

 

28

 

 

 

145

 

 

 

795

 

Total other income, net

 

 

263

 

 

 

28

 

 

 

340

 

 

 

795

 

Net loss and net loss attributable to common stockholders

 

$

(11,279

)

 

$

(26,016

)

 

$

(8,312

)

 

$

(85,553

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss per share attributable to common stockholders-

   basic and diluted

 

$

(0.19

)

 

$

(0.50

)

 

$

(0.14

)

 

$

(1.65

)

Weighted average shares of common stock outstanding-

   basic and diluted

 

 

59,657,677

 

 

 

52,346,715

 

 

 

58,018,550

 

 

 

51,858,032

 

 

See notes to condensed consolidated financial statements

 

 

8


 

Precision Biosciences, Inc.

Condensed Consolidated Statements of Changes in

Stockholders’ Equity

(In thousands, except share amounts)

(Unaudited)

 

 

 

See notes to condensed consolidated financial statements

 

 

Common Stock

 

 

Additional

Paid-In

 

 

 

 

Accumulated

 

 

Treasury

 

 

Total

Stockholder's

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

 

 

Deficit

 

 

Stock

 

 

Equity

 

Balance- January 1, 2020

 

 

51,965,708

 

 

$

 

 

$

316,333

 

 

 

 

$

(177,067

)

 

$

(952

)

 

$

138,314

 

Stock option exercises

 

 

244,999

 

 

 

 

 

 

212

 

 

 

 

 

 

 

 

 

 

 

212

 

Issuance of common stock under employee

   stock purchase plan

 

 

42,620

 

 

 

 

 

 

239

 

 

 

 

 

 

 

 

 

 

 

239

 

Share-based compensation expense

 

 

 

 

 

 

 

 

3,105

 

 

 

 

 

 

 

 

 

 

 

3,105

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(26,836

)

 

 

 

 

 

(26,836

)

Balance- March 31, 2020

 

 

52,253,327

 

 

$

 

 

$

319,889

 

 

 

 

$

(203,903

)

 

$

(952

)

 

$

115,034

 

Stock option exercises

 

 

725,574

 

 

 

 

 

 

148

 

 

 

 

 

 

 

 

 

 

 

148

 

Share-based compensation expense

 

 

 

 

 

 

 

 

3,118

 

 

 

 

 

 

 

 

 

 

 

3,118

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

(32,701

)

 

 

 

 

 

(32,701

)

Balance- June 30, 2020

 

 

52,978,901

 

 

$

 

 

$

323,155

 

 

 

 

$

(236,604

)

 

$

(952

)

 

$

85,599

 

Stock option exercises

 

 

222,983

 

 

 

-

 

 

 

131

 

 

 

 

 

-

 

 

 

-

 

 

 

131

 

Issuance of common stock under employee

   stock purchase plan

 

 

83,608

 

 

 

-

 

 

 

401

 

 

 

 

 

-

 

 

 

-

 

 

 

401

 

Share-based compensation expense

 

 

 

 

 

-

 

 

 

3,709

 

 

 

 

 

-

 

 

 

-

 

 

 

3,709

 

Net loss

 

 

 

 

 

-

 

 

 

-

 

 

 

 

 

(26,016

)

 

 

-

 

 

 

(26,016

)

Balance - September 30, 2020

 

 

53,285,492

 

 

$

 

 

$

327,396

 

 

 

 

$

(262,620

)

 

$

(952

)

 

$

63,824

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance- January 1, 2021

 

 

53,503,124

 

 

$

 

 

$

331,450

 

 

 

 

$

(286,073

)

 

$

(952

)

 

$

44,425

 

Stock option exercises

 

 

676,791

 

 

 

 

 

 

1,297

 

 

 

 

 

 

 

 

 

 

 

1,297

 

Issuance of common stock under employee

   stock purchase plan

 

 

90,796

 

 

 

 

 

 

418

 

 

 

 

 

 

 

 

 

 

 

418

 

Share-based compensation expense

 

 

 

 

 

 

 

 

3,632

 

 

 

 

 

 

 

 

 

 

 

3,632

 

Issuance of common stock to collaboration partners

 

 

3,762,190

 

 

 

 

 

 

 

27,739

 

 

 

 

 

 

 

 

 

 

 

 

27,739

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

(18,689

)

 

 

 

 

 

(18,689

)

Balance- March 31, 2021

 

 

58,032,901

 

 

$

 

 

$

364,536

 

 

 

 

$

(304,762

)

 

$

(952

)

 

$

58,822

 

Stock option exercises

 

 

766,767

 

 

 

 

 

 

1,353

 

 

 

 

 

 

 

 

 

 

 

1,353

 

Share-based compensation expense

 

 

 

 

 

 

 

 

3,896

 

 

 

 

 

 

 

 

 

 

 

3,896

 

Proceeds from issuance of common stock, net of issuance

cost

 

 

1,293,754

 

 

 

 

 

 

 

14,826

 

 

 

 

 

 

 

 

 

 

 

 

14,826

 

Net income

 

 

 

 

 

 

 

 

 

 

 

 

 

21,656

 

 

 

 

 

 

21,656

 

Balance- June 30, 2021

 

 

60,093,422

 

 

$

 

 

$

384,611

 

 

 

 

$

(283,106

)

 

$

(952

)

 

$

100,553

 

Stock option exercises

 

 

414,073

 

 

 

 

 

 

3,393

 

 

 

 

 

 

 

 

 

 

 

3,393

 

Issuance of common stock under employee

   stock purchase plan

 

 

36,091

 

 

 

 

 

 

386

 

 

 

 

 

 

 

 

 

 

 

386

 

Share-based compensation expense

 

 

 

 

 

 

 

 

4,551

 

 

 

 

 

 

 

 

 

 

 

4,551

 

Proceeds from issuance of common stock, net of issuance

cost

 

 

348,432

 

 

 

 

 

 

3,839

 

 

 

 

 

 

 

 

 

 

 

3,839

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

(11,279

)

 

 

 

 

 

(11,279

)

Balance- September 30, 2021

 

 

60,892,018

 

 

$

 

 

$

396,780

 

 

 

 

$

(294,385

)

 

$

(952

)

 

$

101,443

 

 

See notes to condensed consolidated financial statements

 

 

9


 

 

Precision Biosciences, Inc.

Condensed Consolidated Statements of Cash Flows

(In thousands)

(Unaudited)

 

 

 

For the Nine Months Ended September 30,

 

 

 

2021

 

 

2020

 

Cash flows from operating activities:

 

 

 

 

 

 

 

 

Net loss

 

$

(8,312

)

 

$

(85,553

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

6,806

 

 

 

6,587

 

Share-based compensation

 

 

12,079

 

 

 

9,932

 

Loss on disposal of assets

 

 

23

 

 

 

 

Non-cash interest expense

 

 

42

 

 

 

 

Amortization of right-of-use assets

 

 

897

 

 

 

755

 

Non-cash consideration received from collaboration partners

 

 

(17,894

)

 

 

 

Change in fair value of equity investments

 

 

(274

)

 

 

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

Prepaid expenses

 

 

(323

)

 

 

1,262

 

Accounts receivable

 

 

9,512

 

 

 

(9,151

)

Other assets and other current assets

 

 

47

 

 

 

2,185

 

Accounts payable

 

 

240

 

 

 

(1,337

)

Other liabilities and other current liabilities

 

 

(976

)

 

 

2,023

 

Deferred revenue

 

 

2,391

 

 

 

627

 

Lease liabilities and right-of-use assets

 

 

(1,430

)

 

 

(1,264

)

Contract liabilities

 

 

10,000

 

 

 

 

Net cash provided by (used in) operating activities

 

 

12,828